A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: [68Ga]Ga-NeoB
DRUG: [177Lu]Lu-NeoB
DRUG: Capecitabine

Sponsor

Novartis Pharmaceuticals